Engineered immune cells take on lupus kidney disease in early trial
NCT ID NCT06935474
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new treatment called C-CAR168 for people with lupus nephritis that hasn't improved with standard therapies. C-CAR168 is made from a patient's own immune cells, which are modified to target and attack faulty immune cells. The study will enroll 24 adults and focus on safety, tolerability, and finding the right dose. Participants will receive a single infusion after a short course of chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
C-CAR168 (a CAR T-cell therapy targeting CD20 and BCMA proteins)
What this could lead to
If successful, this could point toward a new treatment option for people with lupus nephritis that hasn't responded to standard therapies.
What could go wrong
This is a very early, small study (24 people) focused on safety and dosing. It may not show clear benefit, and CAR T-cell therapy carries risks like severe immune reactions and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AbelZeta, Inc.
Rockville, Maryland, 20850, United States